Author Interviews, Surgical Research / 20.12.2025

Constructing or renovating an operating room is one of the most intricate projects in healthcare design. Every detail, from air circulation to technology integration, plays a critical role in maintaining safety and functionality. Yet the process extends far beyond mechanical systems and sterile finishes. It is about creating an environment where technology, people, and process work together with seamless precision.   The earliest stages of an operating room build begin long before construction starts. Successful projects start with understanding how surgical teams move, communicate, and interact with equipment. Layouts must support clear sightlines, efficient circulation, and ergonomic access to tools and supplies. Architects, clinicians, and engineers often collaborate through detailed simulations to ensure every inch of the space serves a purpose. When this planning is thorough, the final build supports not only compliance but also the daily rhythm of surgical teams.
Author Interviews, Autism, Pediatrics / 20.12.2025

[caption id="attachment_71843" align="aligncenter" width="500"]aba-autism-therapy.jpg Freepix image[/caption] Applied Behavior Analysis, commonly known as ABA therapy, is a widely recognized and evidence-based treatment designed to support individuals, especially children, with autism spectrum disorder (ASD) and other developmental challenges. ABA therapy focuses on understanding behavior, identifying its causes, and using structured techniques to teach positive skills while reducing behaviors that may interfere with learning or daily life. So, what exactly is ABA therapy and how does it work? At its core, ABA therapy uses principles of behavioral science to shape and reinforce desired behaviors. Therapists begin by conducting a detailed assessment of the individual, identifying strengths, challenges, and specific behaviors that need attention. Based on this assessment, a customized plan is created that breaks down complex skills into smaller, achievable steps.
Author Interviews, Public Health / 19.12.2025

[caption id="attachment_71840" align="aligncenter" width="500"]Building Trust Through Community Health Campaigns Photo by Mikhail Nilov[/caption] Trust determines whether people engage with healthcare systems. It shapes whether they show up for screenings, follow treatment plans, or ask for help early instead of waiting until symptoms escalate. Community health campaigns are one of the most effective ways to build that trust because they connect health systems to people where they live, work, and gather. These campaigns turn research into action and public messaging into lived experience. In an era where misinformation spreads quickly and health systems face mounting pressure, trust-building isn’t optional. It’s the backbone of effective public health. Below is a closer look at why community campaigns matter and how they strengthen trust through visibility, transparency, and meaningful participation.

Bringing Health Messaging Into Everyday Spaces

Large institutions often struggle to reach people who feel disconnected from traditional healthcare environments. Community campaigns solve this by bringing information directly to high-traffic settings—schools, local markets, cultural centers, workplaces, and faith organizations. These spaces offer context. They reduce intimidation. They allow people to engage on their own terms. Campaigns rooted in everyday settings also give health workers more accurate readouts of community concerns. They can gather questions, recognize knowledge gaps, and adapt messaging based on direct feedback. This feedback loop strengthens clarity and improves uptake. Physical visibility matters too. Campaign uniforms, event identifiers, or outreach team markers such as branded materials or custom patches make teams recognizable and consistent. This visibility signals professionalism, reduces uncertainty, and encourages people to approach workers comfortably.
Author Interviews, Cognitive Issues, Karolinski Institute, Pediatrics / 18.12.2025

MedicalResearch.com Interview with: Samson Nivins PhD Postdoctoral Researcher, specializing in Perinatal and Pediatric NeurologySamson Nivins PhD Postdoctoral Researcher, specializing in Perinatal and Pediatric Neurology [caption id="attachment_71834" align="alignleft" width="92"]Torkel Klingberg, M.D., Ph.D.Professor of Cognitive Neuroscience at the Stockholm Brain Institute Dr. Klingberg[/caption] Torkel Klingberg, M.D., Ph.D. Professor of Cognitive Neuroscience at the Stockholm Brain Institute Karolinska Institutet, Stockholm Sweden   MedicalResearch.com: What is the background for this study? Response: In the modern era, children’s use of digital media such as watching videos, playing video games, and using social media has increased substantially, often coinciding with a decline in outdoor activities. As many school-aged children now own personal devices, particularly smartphones, it has become easier for them to spend more time on screens than intended. For example, a German survey cited in an EU briefing reported that in 2020, 27% of 8-9-year-olds and 54% of 10-11-year-olds owned a smartphone. In the U.S., ~30% of children own a smartphone by age eight, with many receiving their first device between ages 10 and 11. With growing concerns about screen time, numerous studies have examined its potential consequences and have reported associations between higher screen use and increased ADHD symptoms. However, most of this research has been cross-sectional and has tended to combine different types of digital media such as television, video games, and social media into a single composite measure. This approach may obscure important differences, as various forms of digital media may have distinct effects on ADHD symptoms. To date, relatively few studies have examined the impact of specific types of digital media use on ADHD in a longitudinal framework, and even fewer have accounted for the heritable nature of ADHD. To address these gaps, this U.S. longitudinal study followed children from ages 9-10 to 13-14 years. The study collected repeated measures of daily time spent on specific digital activities, including television and videos, video games, and social media platforms such as TikTok, Instagram, and Facebook. ADHD symptoms specifically inattention and hyperactivity/impulsivity were assessed using parent reports, and analyses adjusted for genetic factors and socioeconomic status.
Author Interviews, Diabetes, Heart Disease, Kidney Disease / 18.12.2025

MedicalResearch.com Interview with: [caption id="attachment_71837" align="alignleft" width="150"]dr_kramer_headshot Dr. Holly Kramer[/caption] Dr. Holly Kramer MD, MPH Professor of Public Health Sciences and Medicine Division of Nephrology and Hypertension Loyola University Chicago MedicalResearch.com: What is the background for this survey? How is UACR measured? Would you explain the significance of albumin in the urine and what creatinine represents? Response: Approximately 36 million people live with type 2 diabetes (T2D) in the U.S. today, with cardiovascular disease (CVD) being the number one cause of death for this patient population. About 1 in 3 adults with T2D has UACR >30 mg/g with prevalence approaching 40% in older patients. Compared to patients with T2D alone, those with elevated UACR face:
    • 5-times higher risk of hospitalization for heart failure
    • 4-times higher risk of CV mortality
    • 3-times higher risk of myocardial infarction
Interestingly, once thought of as a traditional renal biomarker, urine albumin-to-creatinine ratio (UACR) >30 is also a critical biomarker and urgent signal of cardiovascular (CV) risk. When checking UACR, we look at two things: the amount of albumin leaking into the urine and the creatinine level. Albumin shouldn’t be getting through the kidneys’ filters at all, so when we see a UACR >30 mg/g, it’s a sign of systemic vascular endothelial dysfunction. So, if albumin is leaking through the blood vessels inside the kidneys, there’s also damage in the vessels across other organs, like the heart. UACR is such an important early indicator of CV risk in T2D because even small increases follow a clear ‘rule of three’s’. Healthy kidneys secrete 3 mg/g of albumin to creatinine per day, but when it rises to 30 mg/g, a tenfold increase that signals vascular dysfunction and increasing CV risk. At 300 mg/g, another tenfold increase, the damage is more advanced, and CV risk accelerates. Patients with eGFR >60 BUT UACR >30 mg/g can have up to 3.6 times increased risk of CV mortality. As a nephrologist, I’ve been vocal about the potential for this common urine test that we regularly perform, a UACR test, in helping detect CV risk, not just kidney damage, in more patients.
Author Interviews, Lymphoma / 17.12.2025

[caption id="attachment_71819" align="alignleft" width="150"]Marco Davila Dr. Davila[/caption] MedicalResearch.com Interview with: Marco Davila, MD, PhD Hematologist/Oncologist, Senior Vice President and Associate Director for Translational Research at Roswell Park Comprehensive Cancer Center (Buffalo, NY) - study senior author [caption id="attachment_71820" align="alignleft" width="150"]Co-author Meredith Stone, PhDAssistant Director for Cell Therapy Translation in Dr. Davila’s lab at Roswell Park - presenting author Dr. Stone[/caption] Co-author Meredith Stone, PhD Assistant Director for Cell Therapy Translation in Dr. Davila’s lab at Roswell Park - presenting author       MedicalResearch.com: What is the background for this study? Response: While CD19-targeted CAR T cell therapy has garnered clinical success and FDA approval for the treatment of large B cell lymphoma, approximately half of patients suffer from primary resistance or relapse. Increasing evidence suggests that resistance mechanisms are supported by the tumor microenvironment (TME). Cytokines secreted by CAR T cells can remodel the TME, determining the phenotype and function of other immune cells.
Author Interviews, Cancer Research / 17.12.2025

[caption id="attachment_71812" align="alignleft" width="200"]Dr. Magdalena Zak PhD in Molecular BioscienceResearch Associate , Research Associate Instructor of Medicine, The Ear Institute University College London Dr. Zak[/caption] MedicalResearch.com Interview with: Magdalena M. Żak, PhD Zangi Lab Instructor | Cardiovascular Research Institute Instructor | Genetics & Genomic Sciences Icahn School of Medicine at Mount Sinai Hess Center for Science and Medicine New York, NY 10029 MedicalResearch.com: What is the background for this study? Response: mRNA has proven to be a groundbreaking technology through COVID-19 vaccines, and most mRNA-based therapeutics in development today are still focused on vaccines. However, in principle, mRNA could be used for many diseases in which expression of a therapeutic protein would be beneficial. A major reason mRNA is less commonly used outside of vaccines is the lack of robust targeting: for vaccination, broad expression can be acceptable because the goal is antigen production for immune recognition, but for other applications - especially cancer - targeted delivery and minimized off-target expression are critical to reduce side effects.  Current targeting strategies largely rely on lipid nanoparticles (LNPs), which act as lipid “carriers” for systemic delivery. Although LNPs can be designed to show some tissue tropism, this is often limited to organs such as the liver, spleen, and lungs.
ADHD, Author Interviews, Neurology, Pediatrics / 15.12.2025

MedicalResearch.com Interview with: [caption id="attachment_71800" align="alignleft" width="200"]Dr. Ornella Dakwar-KawarHebrew University with Prof. Mor Nahum and Prof. Itai Berger Hebrew University  Dr. Dakwar-Kawar, PhD[/caption] Dr. Ornella Dakwar-Kawar Hebrew University with Prof. Mor Nahum and Prof. Itai Berger Hebrew University  in collaboration with Prof. Jyoti Mishra from the University of California San Diego (UCSD) Prof. Roi Cohen Kadosh from the University of Surre, Dr. Pragathi Priyadharsini and Ashwin Amal from ITT Karpur, India and InnoSphere Ltd MedicalResearch.com: What is the background for this study? Response: Children with ADHD often exhibit aberrant neural activity, specifically imbalances in excitation and inhibition levels alongside dysfunction in brain networks like the frontoparietal network. While our previous research showed that Transcranial Random Noise Stimulation or tRNS improves clinical symptoms, the specific neural modulation effects during cognitive tasks remained unclear. This study investigated these mechanisms by analyzing the aperiodic exponent, a marker of excitation inhibition balance, during an inhibitory control task to compare children with ADHD to healthy controls and assess changes following tRNS combined with cognitive training. 
Author Interviews, Surgical Research / 15.12.2025

[caption id="attachment_71798" align="aligncenter" width="500"]Surgeons who treat hernias regularly hear the same story from patients who have been living with one for months or years: they were hoping it would resolve on its own. It never does. The tissue defect that allows internal organs to protrude through a weakened muscle wall cannot heal without intervention. According to guidelines published by the European Hernia Society, watchful waiting may be appropriate for patients with minimal symptoms, but the majority will eventually require surgical repair.That clinical reality shapes how hernia care works today. The question facing most patients is not whether to treat the problem, but when and how. For those living in Thailand or considering medical care in Bangkok, understanding the options available can make the decision considerably clearer. What Actually Happens Inside the Body A hernia develops when internal tissue, typically fat or a section of intestine, pushes through a weak spot in the surrounding muscle wall. The result is often a visible bulge that becomes more pronounced when standing, coughing, or lifting something heavy. The most common type, an inguinal hernia appearing in the groin area, accounts for roughly 75% of all abdominal wall hernias according to data from the American Hernia Society, and affects men far more frequently than women. Other varieties include femoral hernias (occurring just below the groin, more common in women), umbilical hernias (near the navel), and incisional hernias that develop at the site of previous surgery. Each type carries its own risk profile. Femoral hernias, for instance, have a higher likelihood of becoming trapped or "incarcerated" than inguinal hernias, which is why surgeons often recommend earlier intervention for them. The danger everyone wants to avoid is strangulation, a situation where the blood supply to the trapped tissue gets cut off. This transforms a manageable condition into a surgical emergency. Warning signs include sudden severe pain, nausea, vomiting, and a bulge that becomes tender or changes color. When strangulation occurs, the timeline for surgery shifts from elective to urgent, typically within hours. How Hernia Surgery Has Evolved Hernia repair has changed considerably over the past three decades. The introduction of synthetic mesh in the 1980s reduced recurrence rates dramatically. Studies cited in the HerniaSurge international guidelines show that suture-only repairs carried recurrence rates of roughly 10-15%, while modern mesh-based techniques have brought that figure down to around 1-4% depending on hernia type and surgical approach. Open surgery remains the traditional approach and still has its place. The surgeon makes a single incision directly over the hernia site, repositions the protruding tissue, and reinforces the weakened area with sutures and typically mesh. For very large hernias, complex cases, or patients who have had multiple previous abdominal surgeries, open repair often makes the most sense. Recovery typically takes three to six weeks before returning to full activity. Laparoscopic repair, performed through several small incisions using a camera and specialized instruments, has become increasingly common for straightforward inguinal and umbilical hernias. A 2018 Cochrane review comparing techniques found that laparoscopic repair resulted in faster return to normal activities and lower rates of wound infection, though overall recurrence rates were similar to open repair. Most patients undergoing laparoscopic surgery can resume light work within one to two weeks. Robotic-assisted surgery represents the newest option, offering surgeons enhanced precision and three-dimensional visualization. Some Bangkok hospitals now use robotic systems for complex or recurrent hernias. However, the technology adds cost, and current evidence does not show superior outcomes for routine cases compared to conventional laparoscopy. It remains a valuable tool for specific situations rather than a universal upgrade. Why Patients Choose Bangkok for Hernia Care Thailand's private hospital sector has invested heavily in surgical infrastructure over the past two decades. Major Bangkok hospitals now perform thousands of hernia repairs annually, and several hold Joint Commission International accreditation, the same standard applied to top American hospitals. For international patients, several practical factors come into play beyond clinical quality. Waiting times are typically short. While patients in some national health systems may wait months for elective hernia surgery, Bangkok's private hospitals can often schedule procedures within days. Pricing transparency is another draw. Most hospitals provide itemized cost estimates upfront, and the total expense for hernia repair, including surgeon fees, facility charges, and a short hospital stay, often runs significantly less than comparable procedures in the United States, United Kingdom, or Australia. Language barriers are less of an obstacle than many expect. Major Bangkok hospitals employ multilingual coordinators and maintain medical staff fluent in English, Japanese, Arabic, and other languages. Preoperative consultations can sometimes be conducted via video call before arrival, and detailed discharge instructions are provided in the patient's preferred language. International patients should plan carefully around follow-up care. While most hernia surgeries are straightforward, complications can occasionally arise in the weeks after the procedure. Those traveling from abroad should either plan to stay in Bangkok for at least 10-14 days post-surgery or arrange in advance for their home physician to provide follow-up care upon return. What Recovery Actually Looks Like The experience of recovery varies more than most patients anticipate. Some people feel surprisingly good within 48 hours and need to be reminded not to overdo it. Others experience more discomfort than expected and require a full week before feeling like themselves. Both trajectories fall within normal range, and surgeons generally advise patients to let their body guide the pace. The first few days typically involve managing soreness, some bruising around the incision site, and general fatigue. Most surgeons recommend walking around starting on the day of surgery to promote circulation and reduce the risk of blood clots. Driving usually becomes possible once emergency braking can be performed comfortably, typically after five to seven days for laparoscopic patients. Physical restrictions matter. Lifting anything heavier than about five kilograms should be avoided for at least two weeks, and most guidelines advise waiting four to six weeks before resuming strenuous exercise or heavy manual labor. Return to work depends heavily on job demands. Someone with a desk job might be back within a week; someone whose work involves physical labor may need considerably longer. Chronic pain after hernia surgery remains a concern that the medical community takes seriously. Research published in The Lancet estimates that 10-12% of patients experience some degree of persistent discomfort after inguinal hernia repair. The risk appears lower with laparoscopic approaches and in the hands of high-volume surgeons. Asking a prospective surgeon about their experience level and complication rates is entirely reasonable. Making the Decision For patients living with symptomatic hernia, the calculation is usually straightforward. The surgery is safe, recovery is manageable, and the alternative is a condition that will almost certainly worsen over time. For those with small, asymptomatic hernias, the decision involves more nuance and is worth discussing carefully with a surgeon who can assess individual risk factors. Quality of life often tips the balance. If activities are being avoided because of a hernia, if there is ongoing worry about what might happen, or if daily routine is already affected, surgery is probably the right choice. Modern techniques are reliable, and outcomes from experienced surgeons at well-equipped facilities are consistently good. The best outcomes come from informed patients working with qualified surgeons. Understanding the options, asking direct questions about experience and complication rates, and choosing a facility with strong surgical standards puts patients in the best position to resolve the problem and return to the activities that matter to them. For patients in Bangkok or those considering treatment in Thailand, Samitivej Hospitals offers comprehensive hernia care with experienced general surgeons and modern surgical facilities. Learn more about hernia surgery in Bangkok. References This article draws on the international HerniaSurge guidelines for groin hernia management (2018), guidelines from the European Hernia Society, Cochrane systematic reviews on hernia repair techniques, and epidemiological data from the American Hernia Society. Patients seeking detailed clinical information may consult these sources through medical databases such as PubMed. Freepix image[/caption] Surgeons who treat hernias regularly hear the same story from patients who have been living with one for months or years: they were hoping it would resolve on its own. It never does. The tissue defect that allows internal organs to protrude through a weakened muscle wall cannot heal without intervention. According to guidelines published by the European Hernia Society, watchful waiting may be appropriate for patients with minimal symptoms, but the majority will eventually require surgical repair. That clinical reality shapes how hernia care works today. The question facing most patients is not whether to treat the problem, but when and how.  Understanding the options available can make the decision considerably clearer.

What Actually Happens Inside the Body

A hernia develops when internal tissue, typically fat or a section of intestine, pushes through a weak spot in the surrounding muscle wall. The result is often a visible bulge that becomes more pronounced when standing, coughing, or lifting something heavy. The most common type, an inguinal hernia appearing in the groin area, accounts for roughly 75% of all abdominal wall hernias according to data from the American Hernia Society, and affects men far more frequently than women. Other varieties include femoral hernias (occurring just below the groin, more common in women), umbilical hernias (near the navel), and incisional hernias that develop at the site of previous surgery. Each type carries its own risk profile. Femoral hernias, for instance, have a higher likelihood of becoming trapped or "incarcerated" than inguinal hernias, which is why surgeons often recommend earlier intervention for them. The danger everyone wants to avoid is strangulation, a situation where the blood supply to the trapped tissue gets cut off. This transforms a manageable condition into a surgical emergency. Warning signs include sudden severe pain, nausea, vomiting, and a bulge that becomes tender or changes color. When strangulation occurs, the timeline for surgery shifts from elective to urgent, typically within hours.
Author Interviews, Orthopedics, Pain Research, PT-Rehabilitation / 15.12.2025

[caption id="attachment_71791" align="aligncenter" width="500"]common-elbow-conditions.jpg Freepix image[/caption] The elbow is arguably one of the most used joints in the body. It allows us to bend our arm, which means it is used for most daily activities. From scratching your noise to playing sports, your elbow is a necessity. This means that when something is wrong with your elbow, it can be extremely frustrating and seriously impact your quality of life. Unfortunately, it can be quite difficult to know which elbow condition you’re experiencing, as there are so many of them. Let’s take a look at some of the most common elbow ailments, to give you a better idea of what you might be dealing with.

Tennis Elbow

Tennis elbow is one of the most common elbow conditions. It arises from repetitive stress on the tendons connecting the forearm muscles to the bone. Symptoms include pain on the outside of the elbow, pain that radiates from the elbow down to the back of the hand, and a weakened ability to grip objects. Fortunately, tennis elbow is extremely treatable. For minor cases, rest, icing the elbow,  and the use of over-the-counter pain relievers may be all that is necessary. If these are not enough, physical therapy and the use of corticosteroids may be used. In rare cases, surgery may be needed to repair the tendon.
Author Interviews, Dental Research / 15.12.2025

[caption id="attachment_71787" align="aligncenter" width="500"]groundhog-teeth.jpg Photo by Doug Brown[/caption] Every February 2nd, millions of people watch a groundhog emerge from its burrow to predict spring's arrival, but few stop to consider the remarkable dental adaptations that allow these creatures to thrive underground. Groundhogs possess teeth that continuously grow throughout their lives, self-sharpen through constant use, and maintain perfect alignment without ever seeing a dentist. These evolutionary marvels raise an intriguing question: what can we learn from groundhog teeth that applies to human dental health? Understanding the similarities and differences between groundhog and human teeth helps us appreciate why our dental care routines matter so much and why certain habits damage teeth that lack the groundhog's remarkable regenerative capabilities. Exploring the fascinating biology of groundhog teeth reveals principles about tooth structure, wear patterns, and the importance of proper alignment that translate directly to human dental health—even though our teeth work very differently from these continuously-growing rodent incisors.
Author Interviews, Heart Disease / 12.12.2025

MedicalResearch.com Interview with: [caption id="attachment_71774" align="alignleft" width="150"] Prof. Fairbairn[/caption] Prof. Timothy Fairbairn MBChB, PhD FRCP  and [caption id="attachment_71775" align="alignleft" width="150"] Dr. Bell[/caption] Dr.  Jack Bell Liverpool Heart and Chest Hospital Liverpool, UK   MedicalResearch.com: What is the background for this study? Response: Coronary computed tomography angiography (CCTA) is a non-invasive heart scan used in the first-line investigation of patients with suspected stable coronary artery disease (CAD). While CCTA clearly shows blockages in coronary arteries, it is limited in its ability to estimate reduced blood flow, which is necessary to diagnose angina. An artificial intelligence-based tool (Heartflow) has been developed that analyses CCTA images and provides an estimate of blood flow: CT-derived fractional flow reserve (FFR-CT). The real-world, retrospective English FISH&CHIPS study demonstrated that including FFR-CT as a decision-making tool in the diagnosis of stable CAD reduces the number of subsequent invasive and non-invasive tests performed. Whether FFR-CT could also be used prognostically, to predict future major cardiovascular events, was not fully understood. Previous studies have had small patient numbers, short follow-up and investigated combined cardiovascular outcomes. We performed an analysis on the national FISH&CHIPS population, which was large enough to determine if FFR-CT adds incremental value to traditional cardiovascular risk factors in predicting cardiovascular outcomes and death.
Author Interviews, Duke, Leukemia, Nature / 12.12.2025

MedicalResearch.com Interview with: [caption id="attachment_71759" align="alignleft" width="200"]Dr. Hirschey Dr. Matthew Hirschey[/caption] Matthew Hirschey Ph.D. Associate Professor of Medicine Associate Professor of Cell Biology Associate Professor in Pharmacology and Cancer Biology Member of the Duke Cancer Institute Member of Sarah W. Stedman Nutrition and Metabolism Center Hirschey Lab in the Duke Molecular Physiology Institute, Duke University MedicalResearch.com: What is the background for this study? Would you briefly describe AML and why new therapeutic approaches are needed? Response: Acute myeloid leukemia (AML) is an aggressive blood cancer that begins in the bone marrow and progresses rapidly. While recent advances, particularly the BCL-2 inhibitor venetoclax combined with other agents, have improved outcomes for some patients, many still relapse or don't respond to treatment. The five-year survival rate remains below 30% overall, highlighting an urgent need for new therapeutic strategies. We know that cancer cells rewire their metabolism to fuel rapid growth, and the mitochondria (the cell's powerhouses) play a central role. However, understanding exactly how different metabolic pathways connect and depend on each other has been challenging. We wanted to develop better tools to map these connections and identify new vulnerabilities we could potentially target.
Author Interviews, Education, Nursing / 12.12.2025

7 Ways an Online Nursing Degree The nursing profession continues to evolve rapidly, with healthcare facilities seeking registered nurses who possess advanced knowledge and specialized skills. For working RNs looking to elevate their careers, pursuing an online nursing degree offers a practical pathway to professional growth without sacrificing current employment or personal commitments. Online nursing programs have transformed how registered nurses approach continuing education, providing flexibility that traditional campus-based programs cannot match. These programs maintain rigorous academic standards while accommodating the demanding schedules that nurses face daily. The benefits extend far beyond convenience, offering tangible advantages that can reshape your entire nursing career.
Author Interviews, Hematology, Pediatrics / 08.12.2025

[caption id="attachment_71709" align="alignleft" width="202"]Julian Zorilla, DOPediatric Hematologist/Oncologist Nemours Children’s Health Dr. Zorrilla[/caption] MedicalResearch.com Interview with: Julian Zorrilla, DO Pediatric Hematologist/Oncologist Nemours Children’s Health MedicalResearch.com: What is the background for this study? What are the main findings? Response: Non-factor therapies are a novel treatment approach for people with hemophilia A and B with and without inhibitors. Fitusiran is a first-of-its-kind “rebalancing” agent that provides effective hemostatic control from bleeds in people with hemophilia. This study describes the experience of people with hemophilia who are on fitusiran in regard to minor surgeries. This data shows minor surgeries can be effectively and safely performed for those patients who are on fitusiran for their prophylaxis.  A subset of individuals on fitusiran did not require any other medications to help prevent surgical bleeding.
Author Interviews, Weight Research / 08.12.2025

Editors' note: Retatrutide and Orforglipron are investigational drugs not yet approved by the FDA or available in the US.  This post is for informational purposes only and not medical advice.  Please discuss your weight loss goals with your health care provider. [caption id="attachment_68088" align="aligncenter" width="500"]\weight-loss-semaglutide Pexels[/caption]

Why has the global research community shifted so rapidly from single-agonist therapies like Semaglutide toward multi-agonist therapies?

Semaglutide (a GLP-1 receptor agonist) represented a major pharmacological breakthrough, delivering approximately 11–12% mean weight reduction in obesity trials, far surpassing older treatments. However, emerging clinical data suggest that the therapeutic ceiling for single-pathway modulation has largely been reached. Obesity is not driven by a single metabolic defect. It is a multi-system hormonal disease, involving impaired satiety signaling, dysregulated adipocyte metabolism, altered hepatic lipid handling, and reduced energy expenditure. As a result, the industry has shifted toward multi-agonist therapies capable of simultaneously activating several metabolic pathways. This shift mirrors oncology and cardiology, where combination therapies routinely outperform single-target interventions. In obesity pharmacology, dual and now triple agonists are demonstrating precisely that pattern.
Author Interviews, Gender Differences, Mental Health Research, Race/Ethnic Diversity / 07.12.2025

[caption id="attachment_71691" align="alignleft" width="150"]MedicalResearch.com Interview with:Alexa T. Diianni, MBS Department of Medical Education Geisinger College of Health Sciences Scranton, PA 19409 MedicalResearch.com: What is the background for this study? During a previous study, my research team and I examined the financial conflicts of interest (COIs) between industry and academia- namely those that exist between authors of The American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders (DSM), and industry (1). The DSM is a diagnostic tool widely used for the diagnosis of psychiatric disorders, and is thus of interest in assessing COIs (1,2). We previously found that authors of the DSM-5-TR had received over $14.2m in undisclosed payments from industry (1). Our current study examines the gender and geographic disparities of the DSM-5-TR authors, in relation to these payments. While previous investigations have evaluated financial COIs in recent editions of the DSM (3,4), the demographic information of its authors has not yet been examined. Equitable representation of DSM authors is paramount as this manual serves a diverse population across the United States and beyond. It is important that the authorship of this manual be reflective of the population in which it serves, as there have been reported differences in both the type and prevalence of psychiatric care sought out by gender, as well as varying clinical treatment by geographic location (5-8). MedicalResearch.com: What are the main findings? Of the 225 physicians that were identified as contributors to the DSM-5-TR task force, panels, and cross-cutting review groups, 116 contributors met the inclusion criteria of being a US-based physician with an active National Provider Identifier. Of these included individuals, 69.8% were men and 30.2% were women. Just three states accounted for 43.9% of contributors (New York, 17.2%; California, 14.7%; Massachusetts, 12.1%), while twenty-three states received no author representation. Of the total $14.6m in industry payments received by contributors, $13.2m (91.8%) was received by male contributors. Male contributors thus received an average of $287k in payment, while female contributors received $72k. MedicalResearch.com: What should readers take away from your report? Due to the prevalent use of the DSM, it is important that transparency regarding financial conflicts of interest exists, with COIs minimized moving forward to avoid implicit bias and pro-industry thought (1,9-15). Furthermore, it is important that future editions of the DSM be representative of the population in which it serves. This can be attained by selecting an adequate proportion of male and female contributors for the DSM, which may provide more robust perspectives on current diagnoses. Additionally, representation of contributors from all regions across the US will allow for a more diverse and informed perspective on diagnostic criteria, allowing for improved public health and patient care within the United States. MedicalResearch.com: What recommendations do you have for future research as a result of this study? As gender and geographic disparities were shown to be significant through this study, I believe it would be interesting to address additional areas of demographic disparities among authors. Additional areas to examine may include non-US-based physicians, non-MD/DO authors, as well as ethnic and racial disparities among authors. Finally, similar studies may be applied to additional clinical and diagnostic tools. Diagnostic manuals, such as the DSM, written by a diverse set of individuals, would provide unique perspectives that best reflect the population as a whole, and in turn, benefit patient care. For this reason, it is important that diagnostic manuals, such as the DSM, include a diverse set of authors that can provide adequate input regarding the patient population it serves. MedicalResearch.com: Is there anything else you would like to add? This research received no external funding. First author (AD) is employed by PerkinElmer, working on assignment at GlaxoSmithKline (2023-Present), outside of the submitted work; Last author (BP) contributed to an osteoarthritis research team supported by Pfizer and Eli Lilly (2019-21) and received grants from the Pennsylvania Academic Clinical Research Center, outside of the submitted work. New Paper Diianni AT, Davis LC, Piper BJ. Gender and geographic disparities among DSM-5-TR authors in relation to financial conflicts of interest and industry payments: cross-sectional analysis. BMJ Mental Health. 2025;28:e301913. https://doi.org/10.1136/bmjment-2025-301913 References: 1. Davis LC, Diianni AT, Drumheller SR, Elansary NN, D’Ambrozio GN, Herrawi F, Piper BJ, Cosgrove L. Undisclosed financial conflicts of interest in DSM-5-TR: cross sectional analysis. BMJ. 2024;384. 2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. 2022. 3. Cosgrove L, Krimsky S, Vijayaraghavan M, Schneider L. Financial ties between DSM-IV panel members and the pharmaceutical industry. Psychother Psychosom 2006;75:154-60. doi:10.1159/000091772. Pmid:16636630 4. Cosgrove L, Krimsky S. A comparison of DSM-IV and DSM-5 panel members’ financial associations with industry: a pernicious problem persists. PLoS Med2012;9:e1001190. doi:10.1371/journal.pmed.1001190. Pmid:22427747 5. Piper BJ, Ogden CL, Simoyan OM, Chung DY, Caggiano JF, Nichols SD, et al. (2018) Trends in use of prescription stimulants in the United States and Territories, 2006 to 2016. PLoS ONE 13(11): e0206100. https://doi.org/10.1371/journal.pone.0206100 6. Bareis N, Olfson M, Wall M, Stroup TS. Variation in Psychotropic Medication Prescription for Adults With Schizophrenia in the United States. Psychiatric Services. American Psychiatric Publishing; 2022;73(5):492–500. https://doi.org/10.1176/appi.ps.202000932 7. Tedstone Doherty D, Kartalova-O'Doherty Y. Gender and self-reported mental health problems: predictors of help seeking from a general practitioner. Br J Health Psychol. 2010;15(Pt 1):213-28. 8. Terlizzi EP, Schiller, Jeannine S. Mental health treatment among adults Aged 18–44: United States, 2019–2021. Report. Hyattsville, MD: National Center for Health Statistics; 2022. 9. Grande D, Frosch DL, Perkins AW, Kahn BE. Effect of exposure to small pharmaceutical promotional items on treatment preferences. Arch Intern Med. 2009;169(9):887-893. doi:10.1001/archinternmed.2009.64 10. Institute of Medicine (US) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. In: Graham R, Mancher M, Miller Wolman D, et al., eds. Clinical Practice Guidelines We Can Trust. Washington (DC). National Academies Press, 2011, https://www.ncbi.nlm.nih.gov/books/NBK209539/?report=classic, doi:10.17226/13058. 11. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA 2000;283:373-80. doi:10.1001/jama.283.3.373. Pmid:10647801 12. Moore DA, Tanlu L, Bazerman MH. Conflict of interest and the intrusion of bias. Judgm Decis Mak 2010;5:37-53. doi:10.1017/S1930297500002023 13. Dana J, Loewenstein G. A social science perspective on gifts to physicians from industry. JAMA 2003;290:252-5. doi:10.1001/jama.290.2.252. Pmid:12851281 14. Nejstgaard CH, Bero L, Hróbjartsson A, et al. Association between conflicts of interest and favourable recommendations in clinical guidelines, advisory committee reports, opinion pieces, and narrative reviews: systematic review. BMJ 2020;371:m4234. doi:10.1136/bmj.m4234. Pmid:33298430 15. Thompson DF. The challenge of conflict of interest in medicine. Z Evid Fortbild Qual Gesundhwes 2009;103:136-40. doi:10.1016/j.zefq.2009.02.021. Pmid:19554887 Alexa T. Diianni[/caption] MedicalResearch.com Interview with: Alexa T. Diianni, MBS Department of Medical Education Geisinger College of Health Sciences Scranton, PA 19409 MedicalResearch.com: What is the background for this study? Response: During a previous study, my research team and I examined the financial conflicts of interest (COIs) between industry and academia- namely those that exist between authors of The American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders (DSM), and industry (1). The DSM is a diagnostic tool widely used for the diagnosis of psychiatric disorders, and is thus of interest in assessing COIs (1,2). We previously found that authors of the DSM-5-TR had received over $14.2m in undisclosed payments from industry (1). Our current study examines the gender and geographic disparities of the DSM-5-TR authors, in relation to these payments. While previous investigations have evaluated financial COIs in recent editions of the DSM (3,4), the demographic information of its authors has not yet been examined. Equitable representation of DSM authors is paramount as this manual serves a diverse population across the United States and beyond. It is important that the authorship of this manual be reflective of the population in which it serves, as there have been reported differences in both the type and prevalence of psychiatric care sought out by gender, as well as varying clinical treatment by geographic location (5-8). 
Allergies, Author Interviews, Dermatology / 06.12.2025

[caption id="attachment_71677" align="alignleft" width="200"]Dr. Shaila Gogate, MDColorado Allergy & Asthma Centers Allergist REMIX-1/-2 Investigator  Dr. Gogate[/caption] MedicalResearch.com Interview with: Dr. Shaila Gogate, MD Colorado Allergy & Asthma Centers Allergist REMIX-1/-2 Investigator MedicalResearch.com: What is the background for this study? What are the main findings? A: The Phase III REMIX-1/-2 studies were randomized, double-blind, placebo-controlled studies assessing the efficacy and safety of oral  remibrutinib 25 mg twice daily or placebo over a 24-week double-blind period, followed by a 28-week open-label remibrutinib treatment period. The purpose of this pooled analysis was to examine the early and long-term efficacy data of remibrutinib vs. placebo over time, looking at the mean percentage change from baseline (CFB) in weekly scores of disease activity (UAS7), itch severity (ISS7) and hives severity (HSS7) over 52 weeks. This analysis demonstrated that remibrutinib showed reductions in urticaria symptoms vs. placebo as early as week 1:
    • 38.4% vs. 10.3% in UAS7
    • 37.0% vs. 9.8% in ISS7
    • 39.8% vs. 10.1% HSS7 Greater reductions vs. placebo were seen over 24 weeks and results were observed in the open-label period through week 52 in all remibrutinib-treated patients (including those transitioned from placebo).
Allergies, Author Interviews, Dermatology / 05.12.2025

MedicalResearch.com Interview with: [caption id="attachment_71671" align="alignleft" width="133"]Dr. Giselle Mosnaim MD MSAllergist Division of Allergy and Immunology Department of Medicine Northshore University Health System REMIX-1/-2 Investigator Dr. Mosnaim[/caption] Dr. Giselle Mosnaim MD MS FACAAI Allergist Division of Allergy and Immunology Department of Medicine Northshore University Health System REMIX-1/-2 Investigator MedicalResearch.com: What is the background for this study? What are the main findings? Response: Chronic spontaneous urticaria is a debilitating condition significantly affecting patient quality of life and is characterized by the presence of itch, hives, and/or angioedema (swelling) lasting for greater than 6 weeks, without identifiable trigger. Second-generation H1-antihistamines at standard doses are recommended as first-line treatment for patients with chronic spontaneous urticaria, and can be up-dosed to 4 times the standard dose. However, over 50% of patients continue to have symptoms despite this therapy. Both Remibrutinib and Dupilumab are FDA-approved for the treatment of chronic spontaneous urticaria in adult patients (Remibrutinib ≥ 18 years old and Dupilumab ≥ 12 years old) who remain symptomatic despite second-generation H1-antihistamine treatment. The RECLAIM study is an ongoing head-to-head randomized controlled trial comparing the efficacy of Remibrutinib, an oral Bruton’s tyrosine kinase inhibitor, and Dupilumab, an injectable anti-interleukin-4 and anti-interleukin-13 inhibitor, at early timepoints (4 weeks and earlier) when administered as an add-on therapy in adults with moderate to severe chronic spontaneous urticaria inadequately controlled by second-generation H1-antihistamines.
Author Interviews, Psychedelics / 03.12.2025

Editor’s note: Please remember psychedelics remain illegal in most of the US and are not FDA tested or approved. Psychedelics and hallucinogens can have serious short and long term side effects and should be utilized only with careful medical supervision. [caption id="attachment_71656" align="alignleft" width="200"]dr-daniel-kruger Dr. Kruger[/caption] MedicalResearch.com Interview with: Daniel J. Kruger, PhD Population Studies Center, Institute for Social Research University of Michigan MedicalResearch.com: What is the background for this survey? Response: Multiple studies indicate that psychedelic use is at an all-time high. There are hundreds of clinical trials on the use of psychedelics and psychedelic-derived compounds for potential mental health benefits. Popular books like Michael Pollan’s “How to Change Your Mind” have raised public awareness of these substances and their potential benefits. Legislative changes in some areas have liberalized psychedelic access for therapy and personal use. Still, the vast majority of those who use psychedelics will use them outside of regulated, supervised settings. People are reporting both amazing therapeutic benefits as well as adverse experiences, and sometimes detrimental effects that last well beyond the trip. This study aimed to develop a risk-reduction resource to facilitate safe and successful psychedelic experiences outside of regulated settings. We employed a community-based approach to crowdsource practical recommendations for first-time psychedelic experiences from the psychedelic community.
Addiction, Author Interviews / 03.12.2025

Mad Honey or Grayanotoxin is not FDA approved or standardized in dosing. Discuss your use of Mad Honey or Grayanotoxin products with your health care provider.  Dosing of Mad Honey or Grayanotoxin is variable.  Mad Honey or Grayanotoxin may interfere with other medications and should not be used in individuals with certain health conditions, including liver issues.  Mad honey ingestion may cause dizziness, nausea, vomiting, and diarrhea, based on the quantity ingested. Near fatal low blood pressure and low heart rate has also been reported. Do not use Mad Honey or Grayanotoxin if you are pregnant, nursing or may become pregnant. Do not use Mad Honey or Grayanotoxin products if driving or operating difficult or dangerous machinery. Children should not be exposed to Mad Honey or Grayanotoxin products.

mad-honey-collection

Mad Honey is one of the rarest and most unusual natural products on Earth. It comes mainly from the steep Himalayan cliffs of Nepal, where giant honey bees called Apis laboriosa collect nectar from special rhododendron flowers. The honey is powerful, medicinal and even toxic because of natural chemicals that are found in these flowers. People have been using this honey since centuries to heal, perform rituals and even in ancient warfare. It is famous all over the world today due to its powerful effects, unusual biology, and rich cultural history. Mad Honey is studied by scientists to learn about plant toxins, insect behavior, human physiology and interactions among living organisms in high Himalayan ecosystems. This paper describes the science, biology, environment, and the reported effects of Mad Honey.

What Is Mad Honey?

Mad honey, known locally as "Bhir Mah" or "Khudo" in the Gurung language, gets its unique properties from a natural toxin called grayanotoxin.The compound is extracted out of rhododendron flowers, the national flower of Nepal that bloom in large quantity in the high altitude of 2,500 to 4,000 meters. The process is remarkable. These rhododendron flowers are pollinated by giant Himalayan honeybees known as Apis laboriosa, which is the largest honeybee species in the world measuring 3 centimeters long. It is amazing that these bees have to visit almost 4 million flowers to make one kilogram of honey. They construct their hives on sharp cliff faces and honey collection is one of the most hazardous activities in the world.
Addiction, addiction-treatment, Author Interviews / 02.12.2025

[caption id="attachment_71636" align="aligncenter" width="500"]mat-addiction-treatment Pexels[/caption] MAT combines FDA-approved medications with counseling, behavioral therapy, and support services to treat substance use disorders (especially opioid and alcohol use disorders). The goal is to reduce cravings, ease withdrawal, prevent relapse, and help people build stability in recovery. In Rhode Island, MAT is offered at specialized clinics, community treatment centers, and designated opioid-treatment programs (OTPs), including those connected to statewide initiatives for opioid use support.

Methadone

Methadone is a long-acting opioid agonist that has been used for decades to treat opioid addiction safely and effectively. It attaches to the same brain receptors as other opioids but does so in a slow, controlled way that prevents withdrawal and reduces cravings without producing the intense high associated with opioid misuse. Methadone is dispensed through licensed opioid treatment programs (OTPs) where individuals receive medical monitoring, counseling, and structured support. This medication can be especially helpful for people with long-term or high-intensity opioid use who need daily stability to rebuild their lives.
Addiction, Author Interviews, Mental Health Research / 02.12.2025

[caption id="attachment_71632" align="aligncenter" width="500"]Evidence-Based Therapies Freepix[/caption]

Why Evidence-Based Care Matters

When someone seeks treatment for a substance use disorder, one of the most important factors influencing long-term success is whether the program uses proven, effective therapies. Evidence-based therapies are approaches that have been extensively studied, tested, and shown to help individuals reduce substance use, manage cravings, heal emotionally, and build healthier lives. Research from the National Institute on Drug Abuse consistently shows that combining behavioral therapies with personalized treatment care produces the strongest outcomes. Many high-quality substance abuse treatment facilities in Florida use these therapeutic models to support lasting recovery.
Author Interviews, Mental Health Research, PTSD / 27.11.2025

[caption id="attachment_71569" align="aligncenter" width="500"]CPTSD Pexels[/caption] Complex post-traumatic stress disorder, often shortened to CPTSD or cPTSD, has moved from a niche clinical idea to a term many people now use for their own lived experience. At the same time, it is still not listed as a standalone diagnosis in the Diagnostic and Statistical Manual of Mental Disorders (DSM). That leaves many people asking a very specific question: Will CPTSD be added to the Diagnostic and Statistical Manual of Mental Disorders in 2026? The most accurate answer is that there is currently no official commitment to adding complex PTSD to the DSM in 2026. As of late 2025, CPTSD is recognized in the World Health Organization’s International Classification of Diseases, 11th edition (ICD-11), but not in the DSM-5 Text Revision (DSM-5 TR). Clinicians and researchers are actively debating whether a new CPTSD diagnosis should be included in a future DSM edition, yet no formal decision or fixed timeline has been announced. The question itself opens the door to important issues and questions, which MedicalResearch.com will review and address in this article. How do major diagnostic manuals change over time? Why is CPTSD in the ICD but not in the DSM? And what does any of this mean if you or someone you love is living with the effects of long-term trauma?
Author Interviews, Dermatology / 26.11.2025

Microneedling Improves Skin Texture.jpg

How Microneedling Works Beneath the Surface

Microneedling has become one of the most widely used minimally invasive procedures in dermatology, largely because recent research continues to support its effectiveness. Using fine needles to create tiny controlled micro injuries, modern skin-needling technology activates a predictable healing response that strengthens the skin from within. These micro injuries trigger an immediate inflammatory phase where immune cells move in and growth factors are released. During the proliferative phase, fibroblasts begin producing new collagen and elastin. These structural proteins support firmness and elasticity. The final remodeling phase can last for months as the new collagen fibres organise into stronger more uniform networks that reinforce the skin.
Author Interviews, Cannabis, JAMA / 25.11.2025

Editor’ note:  Cannabis and THCA/HEMP CBD products should have an active ingredient list on the container and have a Certificate of Analysis (COA). Discuss your use of THC, Cannabis or CBD products with your health care provider.  Dosing of CBD is variable, especially since it is not FDA regulated. Cannabis/CBD may interfere with other medications and should not be used in individuals with certain health conditions, including liver issues. CBD skin care products can be absorbed through the skin and have similar effects. Do not use Cannabis products including edibles and CBD if you are pregnant, nursing or may become pregnant. Do not use cannabis products if driving or operating difficult or dangerous machinery. Children should not be exposed to cannabis or CBD products. [caption id="attachment_71501" align="alignleft" width="157"]Dr. Swartz Dr. Swartz[/caption] MedicalResearch.com Interview with: James A. Swartz, PhD Professor, Jane Addams College of Social Work University of Illinois Chicago MedicalResearch.com: What is the background for this study? Response: For the past 5 1/2 years, my project team has been charged with monitoring the public health effects of adult cannabis use legalization in Illinois. To fulfill that obligation, we have monitored state data and have tried to keep informed about ongoing research on cannabis legalization and public health. Cannabinoid hyperemesis syndrome (CHS) rose to the surface of this continual monitoring through a growing number of publications indicating the prevalence of this condition was on the rise and clinical case reports. As context, for any readers unfamiliar with the clinical syndrome, CHS is a paradoxical reaction to long-term, heavy cannabis use. Instead of relieving nausea, cannabis in some people appears to trigger cycles of severe nausea, vomiting, and abdominal pain. Patients often present repeatedly to emergency departments, undergo extensive workups, and only much later does someone connect the dots and consider CHS. Resource use is substantial. CHS visits often involve repeat ED presentations, imaging, laboratory testing, and sometimes hospital admission. Even though CHS is rarely life-threatening, it is not a trivial condition from either the patient’s or the system’s perspective.

Most of the existing literature has been case reports, small series, or single-center studies. Those reports clearly show that CHS can be debilitating and is frequently misdiagnosed, but they don’t tell us much about the bigger picture:

  • How often Cannabinoid hyperemesis syndrome is showing up in emergency departments nationally
  • How those rates have changed over time, especially as cannabis policies and patterns of use have shifted
  • What the typical patient profile looks like at a population level

Our goal was to step back and use a large national emergency department database to describe CHS at scale in the United States from 2016 through 2022.